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The SCOT-HEART Trial. What we observed and what we learned
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a British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
b Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
1. Introduction
The diagnosis of suspected stable angina has come a long way since
the association between chest pain and coronary artery stenosis was
first recognized more than 200 years ago.1 Nevertheless, the assessment
of exertional symptoms remains a common challenge experienced by
cardiologists everywhere. The presenting complaint is frequently aty-
pical in nature, and clinicians are faced with the joint task of avoiding
unnecessary investigations whilst also ensuring the safe and efficient
identification of those individuals with underlying coronary heart dis-
ease. Non-invasive testing strategies have traditionally been dominated
by functional assessment of inducible ischemia and have developed
over time from the exercise electrocardiogram to myocardial perfusion
imaging with single photon emission computed tomography, stress
echocardiography, positron emission tomography and magnetic re-
sonance imaging. In each case, there is an apparent association between
abnormal test results and both the detection of obstructive coronary
artery disease on invasive angiography and the increased risk of ad-
verse cardiovascular events.2–5 However, the prognostic value of ab-
normal results remains inferior to that provided by anatomical eva-
luation of the coronary arteries,6,7 and the use of these tests has not
been demonstrated to improve clinical outcomes within the context of
randomized controlled trials (RCTs).
It is in this context that studies of coronary computed tomography
angiography (CCTA) have generated widespread interest within the
cardiology community. Initial reports described the diagnostic accuracy
of CCTA and highlighted the exquisite sensitivity of this modality.8,9
Subsequently several RCTs have been conducted to provide evidence
regarding the relative clinical advantages of anatomic assessment with
CT compared with functional testing. Recently, we have reported the 5-
year outcomes of the Scottish Computed Tomography of the HEART
(SCOT-HEART) trial wherein we identified an important reduction in
the composite endpoint of coronary heart disease death or non-fatal
myocardial infarction amongst participants randomized to the CCTA
intervention.10 Although these findings have generally been welcomed
by the cardiology community,11 understandable questions remain
concerning the exact mechanisms by which such benefits were
achieved. In examining this uncertainty, we have focussed on several
considerations: the importance of trial design, the plausibility of the
magnitude of treatment effects, and the consistency of our results
within the existing evidence base.
1.1. The design of the SCOT-HEART trial
The design of the SCOT-HEART trial has previously been described
in detail.10,12,13 Nevertheless, it warrants review here as it has im-
portant implications with regards to the interpretation and clinical
application of our results. A pragmatic approach to recruitment was
adopted to ensure broad clinical relevance with enrolment open to
patients aged 18–75 years who had been referred by a primary-care
physician to a dedicated cardiology clinic for patients with suspected
stable angina due to coronary heart disease (CHD). Exclusion criteria
were kept to a minimum and were predominantly related to suspected
acute coronary syndrome or inability to undergo CT scanning (typically
due to advanced renal impairment). Individuals with an established
history of coronary heart disease remained eligible providing they had
not experienced an acute coronary syndrome in the previous 3 months.
All patients underwent routine clinical assessment with 85% of
patients in both study groups proceeding to symptom-limited exercise
electrocardiography. Symptoms (typical, atypical, or non-anginal chest
pain according to the National Institute for Health and Care Excellence
[NICE] definition14), clinical diagnosis, further planned investigations,
and initial treatment strategy were documented at the end of the clinic
attendance. Prior to randomisation, clinicians were prompted to cate-
gorize the likelihood of the diagnosis of coronary heart disease and
angina due to coronary heart disease, and document the subsequent
diagnostic strategy including the need for downstream functional
imaging, or invasive coronary angiography.
The primary diagnostic endpoint of the study was the diagnostic
certainty of patients with angina pectoris secondary to coronary heart
disease at 6 weeks. At this juncture, the treating cardiologist was
prompted to review their patients’ diagnosis and management plan in
view of all available information including the CCTA report (CCTA
intervention arm) or the cardiovascular risk score (standard care arm).
Clinicians were requested to document any changes to their diagnosis,
requirement for additional investigations, or management strategy
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(medical therapy or coronary revascularization). It is this documenta-
tion of management changes that has allowed us to begin exploring
some of the plausible mechanisms that might explain the treatment
effect observed.
In addition to these immediate impacts, there was a pre-specified
principal 5-year outcome comprising a composite of coronary heart
disease death or non-fatal myocardial infarction.13 In keeping with the
pragmatic design of the trial, patients were not required to attend
study-related follow-up visits and all clinical events were identified by
using the patient-unique Community Health Index (CHI) number to
enable linkage to routine electronic health data from the Information
and Statistics Division of the National Health Service (NHS) Scotland.
As this system is in place nationwide, it ensures complete capture of
mortality and hospitalization records, and indeed only 66 patients
(1.6% of the total study cohort) emigrated from Scotland during the
first 5 years of follow-up.10 This approach has previously been de-
monstrated to perform comparably to more traditional diagnostic ad-
judication within the West of Scotland Coronary Prevention Study
(WOSCOPS).15
1.2. CCTA and the diagnosis of coronary heart disease
After recruitment, 4146 patients (mean age 57.1 ± 9.7 years, 44%
women) were randomly assigned (1:1) to standard care plus coronary
calcium score and CCTA (n= 2073), or to standard care alone
(n=2073) with CCTA scans performed using 64 or 320 detector row
scanners across three imaging sites.14 Amongst those assigned to CCTA,
295 defaulted or did not complete their scan whilst 672 (38%) and 452
(25%) of the remainder had CT evidence of non-obstructive or ob-
structive CHD respectively. Compared with standard care, CCTA in-
creased diagnostic certainty (relative risk [RR] 2.56, 95% confidence
interval [CI] 2.33 to 2.79) and the frequency (RR 1.09, 95% CI 1.02 to
1.17) of a diagnosis of coronary heart disease at 6 weeks. The diagnosis
of coronary heart disease at 6 weeks was changed in 27% of those as-
signed to CCTA compared with 1% of participants assigned to standard
care.
1.3. CCTA and downstream investigations
The above diagnostic changes were associated with changes in
planned investigations for 1 in 6 patients assigned to CCTA including
the initial cancellation of 121 functional tests and 29 invasive coronary
angiograms, and the initiation of invasive coronary angiography in 94
participants. These changes were mainly the result of the exclusion or
identification of obstructive coronary heart disease. Interestingly, al-
though overall there was no difference between groups with regards to
the number of invasive coronary angiographic procedures performed
during follow-up (491 [23.6%] versus 502 [24.2%]; hazard ratio (HR)
1.00 (95% CI 0.88 to 1.13), invasive angiography was less likely to
demonstrate normal coronary arteries and more likely to show ob-
structive coronary artery disease in patients assigned to CCTA.16 Fur-
thermore, post-hoc analysis demonstrates a reduced rate of angio-
graphy after the first year amongst the CCTA arm of the trial (HR 0.70,
95% CI 0.52 to 0.95).10
1.4. CCTA and treatment change
Unsurprisingly, changes in diagnostic decision-making were asso-
ciated with changes in subsequent recommendations for medical
therapies and revascularisation procedures. It warrants repeating that
attending clinicians were actively prompted to review their treatment
decisions in the light of the newly available CCTA results. In contrast,
patient management in the standard care group was prompted by ex-
isting estimates of cardiovascular risk and use of further non-invasive
stress imaging at the discretion of the attending clinician.
Correspondingly, nearly 1 in 4 patients in the CCTA group had their
prescribed treatment altered at 6 weeks compared with only 1 in 20
(5%) of those receiving standard care alone. Antiplatelet therapy fell
from 48% (baseline) to 41% (at 1 year) in the standard of care arm
whilst it increased from 49% (baseline) to 52% (at 1 year) in the CCTA
group. In contrast, prescriptions for statins increased in both groups
(standard care: 43%–50%; CCTA: 44%–59%) but this was greater in the
CCTA group (p < 0.001). The greater use of evidence based therapies
amongst patients with abnormal findings on CCTA compared with
functional testing is consistent with prior reports.17 Importantly, pre-
scribing differences regarding preventative therapies were sustained
over the 5 years of follow up and these treatments were selectively
prescribed to patients who had coronary heart disease documented on
the CCTA despite comparable 10-year cardiovascular risk scores. It
should also be remembered that the overall rates of prescriptions of
preventative therapies do not account for how treatments were changed
within the treatment groups, especially those undergoing CCTA, where
both cessation and initiation of therapies occur.
Although there was no overall difference in the frequency of cor-
onary revascularization over 5 years (279 versus 267, HR 1.07, 95% CI
0.91 to 1.27), the pattern of revascularization does appear to differ
between the treatment groups. Specifically, during the first year after
randomization, more patients in the CCTA group underwent coronary
revascularization (246 versus 208, HR 1.21, 95% CI 1.01 to 1.46;
p=0.042), whereas after one year, the rate of coronary revascular-
ization was reduced (33 versus 59, HR 0.59, 95% CI 0.38 to 0.90;
p=0.015).
1.5. CCTA and clinical outcomes
At the time of the initial publication of the trial results, the use of
CCTA appeared to offer improvements in the composite long-term
endpoint of coronary heart disease death or non-fatal myocardial in-
farction, albeit without reaching the threshold for conventional statis-
tical significance (p= 0.053).12 By 5 years, there was a clear reduction
in this endpoint amongst those patients who underwent CCTA com-
pared with standard care alone (48 [2.3%] versus 81 [3.9%]; HR 0.59,
95% CI 0.41 to 0.84; p=0.004). This was primarily driven by a re-
duction in non-fatal myocardial infarction and, as with other trials, we
did not identify any decrease in all-cause mortality. Interestingly, al-
though the 5-year event rates were higher in patients with a prior
history of coronary heart disease, similar relative reductions in fatal and
non-fatal myocardial infarction were evident in those with and without
pre-existing coronary disease.
1.6. Time course of benefit and case ascertainment bias
We have previously described an apparent overlap in event curves
during the first 50 days after randomization (the median time to change
in prescribed therapies amongst the CCTA arm) with the improvement
in outcomes associated with CCTA only beginning after that time-
point.16 This finding offers helpful insight into the mechanisms re-
sponsible for the observed effect size as being predominantly related to
changes in preventative therapies, and provides clear evidence that
event rates were similar in the two trial arms until downstream treat-
ment changes had been implemented. Furthermore, as the CCTA scans
were performed a median of 13 days after randomisation, the lack of an
earlier separation of these curves would tend to undermine the pro-
position that case ascertainment bias is in large part responsible for our
findings.
Given that SCOT-HEART was an open trial and that CCTA increased
the diagnosis of coronary heart disease, one would anticipate that CCTA
would increase the diagnosis of subsequent myocardial infarction and
potentially hinder our ability to see a beneficial effect on this outcome.
We also demonstrated that CCTA prompted more coronary re-
vascularisations in the first year but beyond one year, rates were
markedly reduced. This is in keeping with the CCTA identifying patients
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at risk early on and leading to the initiation of more appropriate pre-
ventative therapies and revascularisation. Patients in the standard of
care arm had unrecognised disease which led to the accrual of later
events and the need for more downstream coronary revascularisations.
Thus, there was an inversion in rates of coronary revascularisations
after one year and it is hard to explain how ascertainment bias could
lead to such a biphasic change in revascularisation rates.
1.7. Plausibility of the magnitude of treatment effect
In determining the planned recruitment for the SCOT-HEART trial,
we used historical data from 20 years ago that reported a 13.1% rate of
coronary heart disease death or non-fatal myocardial infarction and
anticipated a 2.8% absolute risk reduction amongst the CCTA group
(relative risk 0.81, 95% CI 0.69 to 0.95).13,18 In keeping with many
modern cardiovascular trials, the observed number of events was sub-
stantially less than this at 3.1% overall with a 1.6% difference between
the treatment arms. Consequently, the observed relative risk reduction
was more than double the magnitude we expected. Nevertheless, these
relative risk point estimates have substantially overlapping confidence
intervals.
The benefits of preventative therapy trials are well described.
However, it should be remembered that many trials (especially primary
prevention trials) treated a broad population of patients at risk of car-
diovascular disease. Most of these trial participants did not have car-
diovascular disease at either study entry or completion. As such, they
had no chance of benefiting from the intervention and effect size esti-
mates are diluted and underplay the impact of the trial intervention for
those with actual disease. Enriching a population, or better still, iden-
tifying a population with the disease before treatment initiation, will
potentially lead to greater benefits. Indeed, in the JUPITER trial, the
risk stratification step of an elevated high-sensitive c-reactive protein,
enabled the identification of a high-risk population who received a
more marked benefit from rosuvastatin (hazard ratio, 0.56 (95% con-
fidence interval, 0.46 to 0.69), P < 0.001) than has been seen in other
prevention trials.19
Because of the broad inclusion criteria, the trial population of SCOT-
HEART had a spectrum of at risk participants. Although patients had
stable chest pain, many participants had recent onset chest pain, a
particularly high-risk group that represents a form of unstable angina.20
As such, larger relative benefits will be achieved by aspirin therapy, and
early coronary revascularization will reduce the risk of myocardial in-
farction (Table 1). This likely underlies the early divergence of the
event curves seen after 50 days.
Finally, changes in diagnosis can have marked beneficial effects: the
right patient gets the right treatment. Indeed, the introduction of sen-
sitive troponin assays to better diagnose acute myocardial infarction
has been associated with marked reductions in the risk of cardiovas-
cular death and recurrent myocardial infarction (odds ratio 0.42).21
1.8. Mechanism of treatment effect
It is clear that CCTA does not reduce events in isolation, rather it is a
series of responses to the anatomical information CT provides that
governs the benefits we observed. Some of these responses have already
been described, and include increased prescribing of evidence-based
medications and an early increase in coronary revascularization. Others
are more difficult to quantify but may include increased disease
awareness amongst patients prompting greater efforts to achieve
healthy lifestyle changes and improved adherence to prescribed
therapies. In attempting to understand these mechanisms, we have
postulated a biphasic effect of cardiovascular therapies with initial
treatment gains from driven by coronary revascularization and anti-
platelet medications, with more gradual and persistent long-term ben-
efits related to statin use (Table 1). It should be highlighted that the
benefits of treatment arising from each of these therapies represents the
average benefit seen across the respective trial cohorts. An important
advantage of CCTA is the ability to target therapies at individuals ac-
cording to their anatomically defined risk of events, a feature we
identified within the SCOT-HEART trial (Fig. 1).
Myocardial infarction is predominantly caused by acute coronary
thrombosis secondary to plaque rupture or erosion. These events occur
on non-obstructive coronary artery plaques. In both the SCOT-HEART
and the Prospective Multicenter Imaging Study for Evaluation of Chest
Pain (PROMISE) trials, most myocardial infarctions occurred in patients
with non-obstructive coronary artery disease.10,22 Furthermore, over a
half of myocardial infarctions occurred in patients with a normal
functional stress test in the PROMISE trial.6 Thus, the prevention of
myocardial infarction necessitates a technique that can identify non-
obstructive coronary artery disease, and CCTA is the only current non-
invasive technique that can achieve this. In the SCOT-HEART trial,
whilst all subgroups benefited, the numerically largest relative risk
reduction occurred in patients with non-anginal chest pain (0.45, 95%
CI 0.19 to 1.03) and those diagnosed without angina due to coronary
heart disease. This underpins a significant proportion of the benefit: the
treatment of covert non-obstructive coronary artery disease.
2. Consistency of our findings
2.1. Internal consistency
We have previously reported the consistency of our findings across
all major patient subgroups. This included the baseline characteristics
used for minimization of treatment assignment including age, sex, es-
tablished history of coronary heart disease, prior diagnosis of diabetes
mellitus, and treating centre. In addition, there were no differences in
treatment effect identified in relation to estimated 10-year cardiovas-
cular risk or chest pain symptom typicality.23 Moreover, the effect size
was very consistent with time, with similar proportionate reductions in
events between our initial (1.7 years of follow up)15 and recent (4.8
years of follow-up)13 reports.
2.2. External consistency
Although the findings from the SCOT-HEART trial may appear
contrasting to other studies, closer inspection demonstrates important
commonalities. The CAPP24 (Cardiac CT for the Assessment of Pain and
Plaque) and CRESCENT25 (Computed Tomography vs. Exercise Testing
in Suspected Coronary Artery Disease) trials randomized 500 and 350
patients to CCTA respectively with approximately 1 year of follow-up in
each case. Both trials showed increased diagnosis of coronary heart
disease and consequently increased use of preventative medical thera-
pies in the CCTA groups. In addition, despite being clearly under-
powered for clinical events, both trials demonstrated numerically lower
rates of myocardial infarction amongst those assigned to CCTA. How-
ever, perhaps a more appropriate comparator is the larger PROMISE
trial which randomized more than 10,000 North American patients
with suspected stable angina and reported a neutral outcome for the
primary endpoint of death, myocardial infarction, hospitalization for
unstable angina, or major procedural complication after 2 years of
follow up. Compared with SCOT-HEART, the PROMISE trial cohort had
less than half the prevalence of obstructive coronary disease identified
on CCTA.22 In addition to this discrepancy in baseline risk, differences
in trial design that may credibly account for the apparent contrasts in
outcome have previously been described.26 One such difference relates
to the primary endpoint selection. In the SCOT-HEART trial, we chose
to focus on fatal and non-fatal myocardial infarction as the event most
likely to benefit from coronary imaging with CCTA. In the PROMISE
trial, there were directionally opposing effects of myocardial infarction
and hospitalisation for unstable angina leading to an overall neutral
effect. However, the PROMISE investigators did report that CCTA was
associated with a 34% relative reduction in all-cause death and
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myocardial infarction at 12 months (hazard ratio 0.66 (95% confidence
intervals, 0.44–1.00), P= 0.049). In addition to these individual stu-
dies, a meta-analysis of RCTs comparing CCTA with standard care,
published in 2016 identified an incidence rate ratio for myocardial
infarction of 0.69 (95% CI 0.49–0.98; p=0.038),27 a result entirely
consistent with the recent SCOT-HEART findings and confirmed in 2
subsequent larger meta-analyses by independent groups.28,29 Finally,
reductions in myocardial infarction have also been reported in a very
large (n= 86,705) observational Danish registry (HR for CCTA: 0.71,
95% CI 0.61 to 0.82).30
3. Conclusions
The SCOT-HEART trial has demonstrated the use of CCTA in addi-
tion to standard care to result in an important reduction in coronary
heart disease death or non-fatal myocardial infarction. By merit of the
Table 1
Treatment effects observed in prospective trials of cardiovascular therapies according to clinical context.
Therapy Clinical context Risk ratio for myocardial infarction (95% confidence interval) Selected references
Aspirin Unstable angina 0.45 (0.35–0.58) 31,32
Stable coronary disease 0.69 (0.60–0.80) 33
Statins Primary prevention 0.46 (0.30–0.70) 19
Stable coronary disease 0.69 (0.65–0.73) 34
Coronary revascularization Acute coronary syndrome 0.79 (0.63–1.00) 35
Fig. 1. Frequency of prescribing for antiplatelet (top) and
statin (bottom) therapy at 6 weeks in patients with (or-
ange) and without (grey) coronary artery disease on
computed tomography coronary angiography across a
range of 10-year cardiovascular risk as determined from
the ASSIGN score. The lines and corresponding shaded
areas represent the prescribing estimates and 95% con-
fidence interval derived from a regression model. The
ASSIGN is a risk model derived and validated within
Scotland for the determination of cardiovascular risk in
patients without known coronary heart disease (For in-
terpretation of the references to colour in this figure le-
gend, the reader is referred to the web version of this
article.).
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large trial population and availability of long-term outcome data, this is
the first time such a benefit has been definitively demonstrated. Our
findings are internally consistent across treatment centres and patient
subgroups, and are externally consistent with existing evidence from
other randomised controlled trials and observational registries. The
magnitude of the treatment effect appears large, but the confidence
intervals remain overlapping with plausible beneficial effects of pre-
scribed therapies and early coronary revascularization. Ultimately, the
improved diagnosis and treatment of angina pectoris coupled together
with the treatment of covert non-obstructive coronary artery disease
underlies and explains the important beneficial effects of CCTA.
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